| Document |
Document Title |
|
WO/2024/052375A1 |
The present invention relates to an isolated amino acid sequence comprising an amino acid sequence having a sequence identity of at least 70% with the sequence SEQ I D NO: 1, or the nucleotide sequence encoding thereof, for use as a medi...
|
|
WO/2024/055002A1 |
Provided are a fusion protein comprising a mutated kinetochore protein and dCas9. The fusion protein is used in conjunction with guide RNAs target the fusion protein to a location of kinetochore assembly on a centromere such that the fus...
|
|
WO/2024/054425A1 |
The present disclosure provides novel PD1 Ab-IL-15 immunocytokine and VitoKine compositions that aim to target potency-attenuated or bio-activable IL-15 directly to tumor-infiltrating lymphocytes to reduce systemic mechanism-based toxici...
|
|
WO/2024/054863A1 |
The present disclosure relates to an engineered T-cell Receptors (TCRs) capable of binding to an epitope of an epidermal growth factor receptor (EGFR) comprising a T790M mutation presented on human leukocyte antigen-A (HLA-A)*02:01, wher...
|
|
WO/2024/051802A1 |
Provided are a GIPR antibody, a fusion protein thereof with FGF21, a pharmaceutical composition thereof, and use thereof. Further provided is a method of the GIPR antibody and the fusion protein thereof with FGF21 for treating, preventin...
|
|
WO/2024/054829A1 |
Methods and compositions for reducing anxiety disorders (e.g., stress) or symptoms thereof in a subject include probiotic bacterial and fungal organisms. The microbial specificity of each host site is dependent upon the habitat provided ...
|
|
WO/2024/052866A1 |
The invention describes a powdery-mildew resistant grapevine plant and a respective gene, in particular a VviMLO17 gene that can be obtained by genome editing using a gRNA/Cas9 complex inducing a point mutation. Described is a respective...
|
|
WO/2024/052522A1 |
The present invention relates to a binding polypeptide comprising a first binding domain binding a transmembrane E3 ligase; and a second binding domain binding a disease-related polypeptide, wherein said first binding domain comprises a ...
|
|
WO/2024/051817A1 |
The present invention relates to a tumor-targeted fusion protein type medicament precursor taking interleukin 2 as an active ingredient.
|
|
WO/2024/054878A1 |
A nanoparticle comprising a cytoplasmic type citrus leprosis virus-like particle (CiLV-C) p29 protein coat and an optional agent encapsulated with the protein coat is provided herein. The nanoparticles are useful for the delivery of the ...
|
|
WO/2024/052546A1 |
The present invention relates to modified bacteria of the species Yersinia entomophaga which are useful to produce toxins and pesticides such as insecticides. The present invention further relates to a toxin composition and a purified in...
|
|
WO/2024/052434A1 |
The present invention relates to a SoxB1 factor variant comprising (a) the HMG (high-mobility group) domain of any one of the amino acid sequences of SEQ ID NOs: 1 to 3, wherein the amino acid alanine at position 61 of the HMG-domain is ...
|
|
WO/2024/052917A1 |
Methods of treating cancer comprising reducing expression or function of eukaryotic initiation factor 4E-binding protein 1 (EIF4EBP1) or EIF4EBP2 in a cell of the cancer, wherein the function is binding Eukaryotic translation initiation ...
|
|
WO/2024/051796A1 |
Provided in the present disclosure are albumin binding molecules, BCMA binding molecules, fusion proteins, polypeptides and constructs that comprise the albumin binding proteins. Also provided are methods for preparing the albumin bindin...
|
|
WO/2024/054991A1 |
A non-naturally occurring protein dimer is provided and comprises two monomers that are each antagonists of the Na/K-ATPase-Src receptor complex. Each peptide monomer has an amino acid sequence of SEQ ID NO: 1 or a functional fragment or...
|
|
WO/2024/054880A1 |
This invention relates to compositions and methods for modifying homeodomain-leucine zipper transcription factor (HD-Zip) genes in plants. The invention further relates to plants having improved yield characteristics produced using the m...
|
|
WO/2024/054892A1 |
Disclosed herein are engineered peptides for treatment of diseases or conditions such as cancer. Also disclosed herein are pharmaceutical compositions containing engineered peptides of the present disclosure. Also disclosed herein are me...
|
|
WO/2024/055020A2 |
Described herein are methods for engineering proteins and viruses to improve tropism, and proteins and viruses made by using said methods.
|
|
WO/2024/052542A2 |
There is disclosed a peptide mixture comprising a first, second and third peptide. The first peptide is capable of inducing an immune response against a TGFβR2 -1a frameshift mutant protein, wherein the first peptide comprises i) an imm...
|
|
WO/2024/050860A1 |
The present invention relates to the technical field of medical biology, and particularly, to use of RUNX2 as a marker in preparing a diagnosis or detection reagent for a malignant phyllodes tumor. The detection reagent can assist in, ac...
|
|
WO/2024/052901A1 |
The present application, provides, inter alia, a composition including an esterified fatty acid, including a fatty acid comprising 4 to 24 carbon atoms, for use in a method for prevention or treatment of a monogenean infection in an aqua...
|
|
WO/2024/050627A1 |
Purified antigens are usually weakly immunogenic and require the addition of immunostimulatory agents and/or delivery systems to generate robust antigen-specific responses. The present application relates to self-assembling polypeptides ...
|
|
WO/2024/054062A1 |
The present invention pertains to: a novel polypeptide composition for intracellular transfection; and a use thereof. This novel polypeptide composition for intracellular transfection has the advantage of greatly improving the transfecti...
|
|
WO/2024/052906A1 |
Disclosed herein are micropatterned surfaces, particularly in the shape of micro-brushes having a base and a plurality of elongated elements. The micropatterned surfaces suitably biofunctionalized are particularly useful for activation a...
|
|
WO/2024/054985A2 |
The invention features methods of treating a disease or condition associated with elevated activin signaling (e.g., a bone disease, pulmonary hypertension, fibrosis, a muscle disease, a metabolic disease, thrombocytopenia, or neutropenia...
|
|
WO/2024/054864A1 |
The present disclosure relates to compositions and methods for the treatment or prevention of heart disease (e.g., cardiomyopathy) in a subject. In some aspects, the present disclosure relates to vectors encoding, and compositions compri...
|
|
WO/2024/052389A1 |
The present disclosure relates to the fields of molecular biology, more specifically antigen-binding molecule technology. The present disclosure also relates to methods of medical treatment and prophylaxis, particularly cellular immunoth...
|
|
WO/2024/050648A1 |
Methods of treating a subject who has or is at risk of having a chemo-resistant tumor comprising a step of administering a pharmaceutical composition comprising a self-assembled polypeptide complex, which methods result in slowing, inhib...
|
|
WO/2024/054847A1 |
Provided herein are biosynthetic methods for producing thaumatin and related compositions. Uses (e.g., as sweeteners) of the thaumatin produced using the methods are also provided.
|
|
WO/2024/054911A1 |
The present invention applies at least in part to gene therapy treatments of diseases associated with cartilage loss, such as osteoarthritis. The treatments comprise administration of FGF-18 gene therapies, such as into the intra-articul...
|
|
WO/2024/050602A1 |
Disclosed herein are compounds of formula (I) wherein X, L1, and HSA conjugate are as defined herein., methods of preparation thereof, and methods of using thereof for improving cardiac repair, particularly post infarct.
|
|
WO/2024/054336A1 |
A computer-implemented method for learning disentangled representations for T-cell receptors to improve immunotherapy is provided. The method includes introducing (701) a minimal number of mutations to a T-cell receptor (TCR) sequence to...
|
|
WO/2024/051831A1 |
The present invention relates to a constitutive chimeric cytokine receptor, comprising an extracellular domain and a constitutively activated IL-7R mutant. The extracellular domain consists of an effector molecule capable of remodeling t...
|
|
WO/2024/052938A1 |
The present invention relates to a process for the production and purification of recombinant, untagged, trimeric SARS-CoV-2 spike protein. The present invention discloses the process of production recombinant SARS-CoV-2 spike protein yi...
|
|
WO/2024/051787A1 |
Provided are a long-acting acylated insulin derivative and use thereof and a preparation method therefor. The long-acting acylated insulin derivative is formed by connecting a fatty acid side chain to an insulin peptide chain in an acyla...
|
|
WO/2024/050023A1 |
The present disclosure relates to the treatment of a cancer in a human subject where the treatment includes continuing administration of a T cell receptor (TCR) therapy in subjects whose ctDNA levels do not exceed baseline following admi...
|
|
WO/2024/047073A1 |
The invention relates to new toxin-binders for hemodialysis. The invention relates to an apoferritin nanoparticle for use as a toxin-binder in hemodialysis. The apoferritin nanoparticle comprises apoferritin subunits that, when combined ...
|
|
WO/2024/050383A2 |
Provided herein are, inter alia, biosensor recombinant proteins (e.g. ratiometric Ras activity reporter (RasAR)), which provide quantitative measurement of Ras activity in living cells with high spatiotemporal resolution. The biosensor r...
|
|
WO/2024/047587A1 |
Disclosed herein are systems, methods and compositions used for the control of gene expression involving sequence targeting, that may use vector systems related to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and co...
|
|
WO/2024/049348A1 |
The present invention provides a modified immune cell, which comprises a T cell receptor (TCR) capable of specifically targeting hepatitis B surface antigen (HBsAg) and a chimeric conversion receptor. The chimeric conversion receptor use...
|
|
WO/2024/050524A1 |
Provided herein are compositions for increasing Apolipoprotein L1 (ApoL1) in target cells. The ApoL1 can be a recombinant protein or an endogenous protein optionally in a ApoL1-containing complex. Antibodies and other binding molecules t...
|
|
WO/2024/047178A1 |
Disclosed is a method and compounds useful for performing said method for simultaneous synthesis of a plurality of oligonucleotide molecules, and more specifically for orthogonal synthesis of at least two different oligonucleotide molecu...
|
|
WO/2024/050501A2 |
The present disclosure, relates, in general to analogs of proline-rich polypeptide 1 (PRP-1) designated tyrosine peptides (TYR peptide) that are useful to treat cancer, such as sarcomas, carcinomas and leukemias or liquid cancers.
|
|
WO/2024/048418A1 |
Provided is a diagnostic antibody that is capable of detecting PD-L1 in tumors for novel therapies for feline tumors targeting PD-1/PD-L1. The anti-PD-L1 antibody contains: (a) an L-chain having CDR1 that has the amino acid sequence ES...
|
|
WO/2024/049232A1 |
The present invention relates to a fusion polypeptide comprising a polypeptide containing a transmembrane domain (TMD) having the C-terminus and the N-terminus to which a polypeptide of general formula I is bound, and the fusion polypept...
|
|
WO/2024/049307A1 |
The present disclosure provides microbial strains, including fungal and yeast strains, which are useful for protein expression. Also provided are expression constructs, expression systems, growth media, and methodology for achieving expr...
|
|
WO/2024/049161A1 |
The present invention relates to a novel antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1, a chimeric antigen receptor comprising an antigen-binding variable fragment of the antibody, immune cells expres...
|
|
WO/2024/047155A1 |
The present invention relates to novel host cells capable of degrading starch and/or utilizing starch as a carbon source wherein said host cell comprising one or more of the following sequences: (a) a polypeptide having at least 97% iden...
|
|
WO/2024/050285A2 |
Compositions and methods are provided for preventing or treating obesity and/or overweight, and managing body weight. Compositions comprise partial agonists of the leptin receptor (lepr), including variant leptin polypeptides, which part...
|
|
WO/2024/050478A1 |
Provided herein are chimeric receptors comprising an amyloid-reactive peptide, as well as cells comprising the chimeric receptors. Also provided herein are methods of treating amyloid-based diseases by administering a cell comprising a c...
|
